Quest Diagnostics (DGX) says U.S. regulators granted a de novo classification petition for the company's Stratify JCV Antibody Elisa testing service. The approval means doctors can now test for the risk of a potentially fatal brain infection caused by Tysabri, a multiple sclerosis treatment sold by Biogen Idec (BIIB) and Elan (ELN).
From other sites
at Zacks.com (Apr 10, 2015)
at Zacks.com (Mar 12, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs